纽交所上市公司Nuvation Bio于2024年4月10日宣布，完成以全股票交易方式收购创新生物制药企业AnHeart Therapeutics Ltd.（“葆元医药”）。海问为Nuvation Bio在本次交易中担任中国法律顾问，为客户提供了多领域一体化的高质量服务。项目团队由医药组合伙人吴婷、劳动组合伙人吴琼以及公司组合伙人巫珊联合组成。其他主要团队成员还包括潘冰、王旭颖、陈青青、龙小宁。

Nuvation Bio, a New York Stock Exchange listed company, announced on April 10 2024 the completion of acquisition of AnHeart Therapeutics Ltd. (“AnHeart”), an innovative biotech company, in an all-stock transaction. Haiwen & Partners acted as PRC legal counsel to Nuvation Bio in this transaction, and has provided integrated and high-quality legal services to the client in this transaction. The Haiwen team includes Life Science Partner Wu Ting (Tina Wu), Labor Law Partner Wu Qiong and Corporate Partner Wu Shan. Other key team members include Pan Bing, Wang Xuying, Chen Qingqing and Long Xiaoning.

收购完成后，Nuvation Bio目前拥有葆元医药的全部资产，包括葆元医药主要管线产品Taletrectinib。Taletrectinib是治疗ROS1融合阳性非小细胞肺癌的下一代ROS1抑制剂，目前正处于关键性II期试验，包括在中国开展的TRUST-I（NCT04395677）试验和TRUST-II (NCT04919811)，一项全球性关键试验。Taletrectinib已获得美国食品药品监督管理局（FDA）和中国国家药品监督管理局（NMPA）授予的突破性疗法认定，NMPA已受理并授予Taletrectinib新药优先审评资格。Nuvation Bio创始人David Hung表示，Taletrectinib具有同类最佳的潜在优势，可以克服现有疗法的显著局限性，Nuvation Bio将在葆元医药已有研发进展基础上再接再厉。

With the acquisition’s completion, Nuvation Bio now owns all of AnHeart’s assets including AnHeart’s lead asset Taletrectinib. Taletrectinib is a next-generation ROS1-inhibitor currently in pivotal Phase II trials for ROS1-positive non-small cell lung cancer (NSCLC), including TRUST-I (NCT04395677) in China and TRUST-II (NCT04919811), a global pivotal study. Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA). China NMPA has accepted and granted Priority Review Designation to New Drug Applications for Taletrectinib. The Founder of Nuvation Bio, David Hung, said that Taletrectinib has a potentially best-in-class profile that may overcome the significant limitations of existing therapies and Nuvation Bio intends to build on the progress that AnHeart team made to date.

Nuvation Bio是一家成立于2018年的美国生物制药公司，专注于开发肿瘤领域差异化的新型候选疗法，2021年实现在纽交所上市。其产品管线包括处于临床阶段的溴结构域和超末端结构域（BET）抑制剂，以及新型小分子药物共轭物（DDC）平台中的临床候选药物。

Nuvation Bio, founded in 2018, is a US-based biopharmaceutical company developing differentiated and novel therapeutic candidates in oncology and listed on the New York Stock Exchange in 2021. Nuvation Bio’s pipeline includes a clinical stage bromodomain and extra-terminal (BET) inhibitor program and a clinical candidate from the novel, small molecule drug-drug conjugate (DDC) platform.

葆元医药由王钧源博士、颜冰博士和郑利华博士于2018年联合创立，是一家致力于为癌症患者开发新一代精准疗法的生物制药集团公司，资产包括ROS1抑制剂Taletrectinib和mIDH1抑制剂Safusidenib。

AnHeart Therapeutics, co-founded in 2018 by Dr. Wang Junyuan, Dr. Yan Bing and Dr. Zheng Lihua, is a biotech company developing novel precision therapies for people with cancer, with assets including the ROS1-inhibitor Taletrectinib and the mIDH1-inhibitor Safusidenib.